
XENCOR Patents

Matching "XENCOR" by Owner.

IPMonitor
Patents

Contents

Alerts	3
"XENCOR"	3
Terms and Conditions	5
General	5
Disclaimer of warranty and limitation of liability	5
Copyright	5
Arbitration	5

Alerts

"XENCOR"

56 results matching "'XENCOR'" by Owner.

Number	Title	Owner
2002306402	PROTEIN DESIGN AUTOMATION FOR DESIGNING PROTEIN LIBRARIES WITH ALTERED IMMUNOGENICITY	XENCOR, INC.
2002311888	NUCLEIC ACIDS AND PROTEINS WITH THIOREDOXIN REDUCTASE ACTIVITY	XENCOR ; SYNGENTA PARTICIPATIONS AG
2002327442	Protein design automation for protein libraries	XENCOR
2002334689	RNA DEPENDENT RNA POLYMERASE MEDIATED PROTEIN EVOLUTION	XENCOR
2002334766	Protein based TNF-alpha variants for the treatment of TNF-alpha related disorders	Xencor
2002335613	BIOCHIPS COMPRISING NUCLEIC ACID/PROTEIN CONJUGATES	XENCOR, INC.
2002255451	PROCARYOTIC LIBRARIES AND USES	XENCOR, INC.
2002251999	METHODS AND COMPOSITIONS FOR THE CONSTRUCTION AND USE OF FUSION LIBRARIES USING COMPUTATIONAL PROTEIN DESIGN METHODS	XENCOR, INC.
2002257056	USE OF NUCLEIC ACID LIBRARIES TO CREATE TOXICOLOGICAL PROFILES	XENCOR, INC.
2002254181	METHODS AND COMPOSITIONS FOR THE CONSTRUCTION AND USE OF FUSION LIBRARIES	XENCOR
2003207464	DOMINANT NEGATIVE PROTEINS AND METHODS THEREOF	XENCOR
2003217174	NOVEL VARIANTS OF RANKL PROTEIN	XENCOR
2003217912	ANTIBODY OPTIMIZATION	XENCOR
2003276846	THROMBOPOIESIS-STIMULATING PROTEINS HAVING REDUCED IMMUNOGENICITY	XENCOR
2003277088	INTERFERON VARIANTS WITH IMPROVED PROPERTIES	XENCOR
2003279719	Optimized Fc variants and methods for their generation	Xencor Inc.
2003295458	NUCLEIC ACIDS AND PROTEINS WITH THIOREDOXIN REDUCTASE ACTIVITY	XENCOR
2004203224	Protein design automation for protein libraries	Xencor
2004204942	Novel proteins with altered immunogenicity	Xencor, Inc.
2001245411	Design and discovery of protein based TNF-alpha variants for the treatment of TNF-alpha related disorders	Xencor
2004227937	Methods for rational pegylation of proteins	Xencor, Inc
2005239700	Design and discovery of protein based TNF-alpha variants for the treatment of TNF-alpha related disorders	Xencor
2004236160	Optimized Fc variants and methods for their generation	Xencor Inc.

Number	Title	Owner
2004220078	BAFF mutants with at least one amino acid substitution and methods of their production	Xencor, Inc.
2004253847	Interferon variants with improved properties	Xencor, Inc.
2004279895	Protein based TNF-alpha variants for the treatment of TNF-alpha related disorders	Xencor, Inc.
2004297616	Methods of generating variant proteins with increased host string content and compositions thereof	Xencor, Inc.
2004298058	Protein engineering with analogous contact environments	Xencor, Inc.
2005227326	Immunoglobulin variants outside the Fc region	Xencor, Inc
2005230854	BMP-7 variants with improved properties	Xencor, Inc.
2005272993	Optimized Fc variants	Xencor, Inc
2005245910	C1q family member proteins with altered immunogenicity	Xencor, Inc.
2006203832	Adiponectin variants	Xencor
2005304624	Fc variants with altered binding to FcRn	Xencor, Inc
2006204791	Antibodies and Fc fusion proteins with altered immunogenicity	Xencor, Inc.
2006230413	Fc variants with optimized properties	Xencor, Inc
2006304100	Anti-glypican-3 antibody	Chugai Seiyaku Kabushiki Kaisha ; Xencor, Inc.
2006299429	Fc variants with optimized Fc receptor binding properties	Xencor, Inc
2006302254	Optimized anti-CD30 antibodies	Xencor, Inc
2008229860	Optimized Fc variants and methods for their generation	Xencor, Inc
2006268227	Optimized anti-Ep-CAM antibodies	Xencor, Inc.
2008261120	Optimized Fc variants and methods for their generation	Xencor, Inc
2009200518	Optimized Fc Variants and Methods for Their Generation	Xencor, Inc
2007285976	Optimized antibodies that target CD19	Xencor, Inc
2007299843	Optimized antibodies that target HM1.24	Xencor, Inc
2008207898	Optimized CD40 antibodies and methods of using the same	Xencor, Inc
2009203094	Protein based TNF-alpha variants for the treatment of TNF-alpha related disorders	Xencor, Inc
2008260498	Methods and compositions for inhibiting CD32b expressing cells	Moore, G. ; Igor, V. ; Chu, S. ; Karki, S. ; Xencor, Inc. ; Lazar, G. ; Desjarlais, J.
2008319144	Fc variants with altered binding to FcRn	Xencor, Inc.
2008345242	Fc variants with altered binding to FcRn	Xencor, Inc
2009206506	Optimized CD40 antibodies and methods of using the same	Xencor, Inc.
2011200066	Fc variants with altered binding to FcRn	Xencor, Inc.
2009293143	Novel compositons and methods for treating IgE-mediated disorders	Xencor, Inc.
2011202115	Optimized Anti-CD30 Antibodies	Xencor, Inc.
2011203503	Optimized antibodies that target CD19	Xencor, Inc.
2011217770	Novel CTLA4-IG immunoadhesins	Xencor, Inc.

Terms and Conditions

General

The information provided in this report is not in the nature of legal or other professional advice.

The information provided in this report is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals regarding any information in this report.

Patents, patent applications, trademarks and trademark applications shown as lapsed or ceased may be restored at a later date.

Disclaimer of warranty and limitation of liability

Neither IPMonitor, its affiliates nor any of their respective employees, agents, third party content providers or licensors warrant that the information contained in this report is error free; nor do they make any warranty as to the accuracy, reliability or content of any information in this report.

This report is provided on an "as is" basis; to the maximum extent permitted by law, IPMonitor disclaims all representations and warranties, express or implied, with respect to any information contained in this report. In addition, IPMonitor does not represent or warrant that the information contained in this report is accurate, complete or current.

This disclaimer of liability applies to any damages or injury caused by any failure of performance, error, omission, interruption, deletion, defect, delay in operation or transmission, computer virus, communication line failure, theft or destruction or unauthorized access to, alteration of, or use of record, whether for breach of contract, tortious behavior, negligence, or under any other cause of action.

Copyright

The content of this report may be protected by copyright laws and treaties around the world and all rights relating to the same are reserved. Any paper or digital copies of this report are not to be modified or any illustrations or any graphics used separately from any accompanying text.

Arbitration

Any dispute or difference whatsoever arising out of or in connection with this report shall be submitted to arbitration in accordance with, and subject to, The Institute of Arbitrators & Mediators Australia Rules for the Conduct of Commercial Arbitrations.

IPMonitor reserves the right to update the Terms and Conditions at any time without notice. Please see the full Terms and Conditions at www.IPMonitor.com.au/trademarks/info/terms